{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:42:13Z","timestamp":1794667333952,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["JP19K18683"],"award-info":[{"award-number":["JP19K18683"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of poly (ADP-ribose) polymerase (PARP) inhibitors is expected to increase, but their effect on fertility is still unclear. The aim of this study was to investigate the effect of PARP inhibitors on ovarian function. In an in vitro study, cultures of ovaries and granulosa cells (GCs) exposed to the PARP inhibitor olaparib were evaluated by real-time RT-PCR, histological study, and hormone assays. In an in vivo study, mice were administered olaparib orally and evaluated via in vitro fertilization (IVF), follicle count, immunohistochemical staining, and real-time RT-PCR. In vitro, the gene expression of GC markers decreased in the olaparib-treated group. Olaparib also negatively affected estradiol production and the expression of GC markers in cultured GCs, with abnormal morphology of GCs observed in the treated group. The follicle number indicated depletion of follicles due to atretic changes in the treatment group, both in vitro and in vivo. Also, olaparib reduced the number of retrieved oocytes and the fertilization rate of IVF, but they recovered after 3\u00a0weeks of cessation. Our results indicate that olaparib is toxic to ovaries.<\/jats:p>","DOI":"10.1038\/s41598-020-74087-9","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T10:05:00Z","timestamp":1602583500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Poly (ADP-ribose) polymerase inhibitor exposure reduces ovarian reserve followed by dysfunction in granulosa cells"],"prefix":"10.1038","volume":"10","author":[{"given":"Kentaro","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seido","family":"Takae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiemi","family":"Shinya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arby Jane","family":"Igualada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"74087_CR1","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1200\/jco.2013.49.2678","volume":"31","author":"AW Loren","year":"2013","unstructured":"Loren, A. W. et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 31, 2500\u20132510. https:\/\/doi.org\/10.1200\/jco.2013.49.2678 (2013).","journal-title":"J. Clin. Oncol."},{"key":"74087_CR2","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1200\/jco.2018.78.1914","volume":"36","author":"K Oktay","year":"2018","unstructured":"Oktay, K. et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J. Clin. Oncol. 36, 1994\u20132001. https:\/\/doi.org\/10.1200\/jco.2018.78.1914 (2018).","journal-title":"J. Clin. Oncol."},{"key":"74087_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/cncr.26284","volume":"118","author":"JK Litton","year":"2012","unstructured":"Litton, J. K. et al. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer 118, 321\u2013325. https:\/\/doi.org\/10.1002\/cncr.26284 (2012).","journal-title":"Cancer"},{"key":"74087_CR4","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1200\/jco.2008.16.0812","volume":"26","author":"A Ashworth","year":"2008","unstructured":"Ashworth, A. A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26, 3785\u20133790. https:\/\/doi.org\/10.1200\/jco.2008.16.0812 (2008).","journal-title":"J. Clin. Oncol."},{"key":"74087_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917. https:\/\/doi.org\/10.1038\/nature03443 (2005).","journal-title":"Nature"},{"key":"74087_CR6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921. https:\/\/doi.org\/10.1038\/nature03445 (2005).","journal-title":"Nature"},{"key":"74087_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ygyno.2012.03.006","volume":"125","author":"RB Dann","year":"2012","unstructured":"Dann, R. B. et al. BRCA1\/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol. Oncol. 125, 677\u2013682. https:\/\/doi.org\/10.1016\/j.ygyno.2012.03.006 (2012).","journal-title":"Gynecol. Oncol."},{"key":"74087_CR8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/bjc.2016.348","volume":"115","author":"JA Ledermann","year":"2016","unstructured":"Ledermann, J. A. et al. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br. J. Cancer 115, 1313\u20131320. https:\/\/doi.org\/10.1038\/bjc.2016.348 (2016).","journal-title":"Br. J. Cancer"},{"key":"74087_CR9","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/s1470-2045(16)30376-x","volume":"17","author":"JA Ledermann","year":"2016","unstructured":"Ledermann, J. A. et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 17, 1579\u20131589. https:\/\/doi.org\/10.1016\/s1470-2045(16)30376-x (2016).","journal-title":"Lancet Oncol."},{"key":"74087_CR10","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/cncr.29995","volume":"122","author":"UA Matulonis","year":"2016","unstructured":"Matulonis, U. A. et al. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer 122, 1844\u20131852. https:\/\/doi.org\/10.1002\/cncr.29995 (2016).","journal-title":"Cancer"},{"key":"74087_CR11","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann, J. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852\u2013861. https:\/\/doi.org\/10.1016\/S1470-2045(14)70228-1 (2014).","journal-title":"Lancet Oncol."},{"key":"74087_CR12","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa1105535 (2012).","journal-title":"N. Engl. J. Med."},{"key":"74087_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrc2583","volume":"9","author":"TA Yap","year":"2009","unstructured":"Yap, T. A., Carden, C. P. & Kaye, S. B. Beyond chemotherapy: Targeted therapies in ovarian cancer. Nat. Rev. Cancer 9, 167. https:\/\/doi.org\/10.1038\/nrc2583 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"74087_CR14","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274\u20131284. https:\/\/doi.org\/10.1016\/S1470-2045(17)30469-2 (2017).","journal-title":"Lancet Oncol."},{"key":"74087_CR15","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Ovarian cancer version 2. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf (2018)."},{"key":"74087_CR16","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1810858 (2018).","journal-title":"N. Engl. J. Med."},{"key":"74087_CR17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.canlet.2016.03.017","volume":"375","author":"C Deben","year":"2016","unstructured":"Deben, C. et al. APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines. Cancer Lett. 375, 313\u2013322. https:\/\/doi.org\/10.1016\/j.canlet.2016.03.017 (2016).","journal-title":"Cancer Lett."},{"key":"74087_CR18","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1158\/1535-7163.Mct-13-0683","volume":"13","author":"M Tahara","year":"2014","unstructured":"Tahara, M. et al. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks. Mol. Cancer Ther. 13, 1170\u20131180. https:\/\/doi.org\/10.1158\/1535-7163.Mct-13-0683 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"74087_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/dote.12299","volume":"29","author":"L Zhan","year":"2016","unstructured":"Zhan, L. et al. Novel poly (ADP-ribose) polymerase inhibitor, AZD2281, enhances radiosensitivity of both normoxic and hypoxic esophageal squamous cancer cells. Dis. Esophagus 29, 215\u2013223. https:\/\/doi.org\/10.1111\/dote.12299 (2016).","journal-title":"Dis. Esophagus"},{"key":"74087_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2014.02.010","volume":"348","author":"S Chen","year":"2014","unstructured":"Chen, S. et al. Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Lett. 348, 20\u201328. https:\/\/doi.org\/10.1016\/j.canlet.2014.02.010 (2014).","journal-title":"Cancer Lett."},{"key":"74087_CR21","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1016\/j.ejca.2007.07.010","volume":"43","author":"L Tentori","year":"2007","unstructured":"Tentori, L. et al. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur. J. Cancer 43, 2124\u20132133. https:\/\/doi.org\/10.1016\/j.ejca.2007.07.010 (2007).","journal-title":"Eur. J. Cancer"},{"key":"74087_CR22","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.bbrc.2006.09.160","volume":"350","author":"M Rajesh","year":"2006","unstructured":"Rajesh, M. et al. Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. Biochem. Biophys. Res. Commun. 350, 1056\u20131062. https:\/\/doi.org\/10.1016\/j.bbrc.2006.09.160 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"74087_CR23","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.bbrc.2006.09.049","volume":"350","author":"M Rajesh","year":"2006","unstructured":"Rajesh, M. et al. Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Biochem. Biophys. Res. Commun. 350, 352\u2013357. https:\/\/doi.org\/10.1016\/j.bbrc.2006.09.049 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"74087_CR24","first-page":"371","volume":"6","author":"JB Bruno","year":"2009","unstructured":"Bruno, J. B. et al. Angiogenic factors and ovarian follicle development. Anim. Reprod. 6, 371\u2013379 (2009).","journal-title":"Anim. Reprod."},{"key":"74087_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1210\/edrv.21.2.0394","volume":"21","author":"EA McGee","year":"2000","unstructured":"McGee, E. A. & Hsueh, A. J. Initial and cyclic recruitment of ovarian follicles. Endocr. Rev. 21, 200\u2013214. https:\/\/doi.org\/10.1210\/edrv.21.2.0394 (2000).","journal-title":"Endocr. Rev."},{"key":"74087_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/oxfordjournals.humrep.a136365","volume":"1","author":"A Gougeon","year":"1986","unstructured":"Gougeon, A. Dynamics of follicular growth in the human: A model from preliminary results. Hum. Reprod. 1, 81\u201387. https:\/\/doi.org\/10.1093\/oxfordjournals.humrep.a136365 (1986).","journal-title":"Hum. Reprod."},{"key":"74087_CR27","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/oxfordjournals.humrep.a137513","volume":"6","author":"SC Chappel","year":"1991","unstructured":"Chappel, S. C. & Howles, C. Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum. Reprod. 6, 1206\u20131212. https:\/\/doi.org\/10.1093\/oxfordjournals.humrep.a137513 (1991).","journal-title":"Hum. Reprod."},{"key":"74087_CR28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.bbrc.2007.09.061","volume":"363","author":"N Kosaka","year":"2007","unstructured":"Kosaka, N., Sudo, N., Miyamoto, A. & Shimizu, T. Vascular endothelial growth factor (VEGF) suppresses ovarian granulosa cell apoptosis in vitro. Biochem. Biophys. Res. Commun. 363, 733\u2013737. https:\/\/doi.org\/10.1016\/j.bbrc.2007.09.061 (2007).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"74087_CR29","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1172\/jci18740","volume":"112","author":"RC Zimmermann","year":"2003","unstructured":"Zimmermann, R. C. et al. Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development. J. Clin. Investig. 112, 659\u2013669. https:\/\/doi.org\/10.1172\/jci18740 (2003).","journal-title":"J. Clin. Investig."},{"key":"74087_CR30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1071\/RD08181","volume":"21","author":"JB Bruno","year":"2009","unstructured":"Bruno, J. B. et al. Expression of vascular endothelial growth factor (VEGF) receptor in goat ovaries and improvement of in vitro caprine preantral follicle survival and growth with VEGF. Reprod. Fertil. Dev. 21, 679\u2013687. https:\/\/doi.org\/10.1071\/RD08181 (2009).","journal-title":"Reprod. Fertil. Dev."},{"key":"74087_CR31","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.bbrc.2016.12.070","volume":"483","author":"DH Kim","year":"2017","unstructured":"Kim, D. H. et al. The effect of poly(ADP-ribosyl)ation inhibition on the porcine cumulus-oocyte complex during in vitro maturation. Biochem. Biophys. Res. Commun. 483, 752\u2013758. https:\/\/doi.org\/10.1016\/j.bbrc.2016.12.070 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"74087_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012526","author":"T Osada","year":"2010","unstructured":"Osada, T. et al. PolyADP-ribosylation is required for pronuclear fusion during postfertilization in mice. PLoS ONE https:\/\/doi.org\/10.1371\/journal.pone.0012526 (2010).","journal-title":"PLoS ONE"},{"key":"74087_CR33","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/bies.20085","volume":"26","author":"JC Ame","year":"2004","unstructured":"Ame, J. C., Spenlehauer, C. & de Murcia, G. The PARP superfamily. BioEssays 26, 882\u2013893. https:\/\/doi.org\/10.1002\/bies.20085 (2004).","journal-title":"BioEssays"},{"key":"74087_CR34","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1200\/jco.2006.06.5888","volume":"24","author":"SJ Lee","year":"2006","unstructured":"Lee, S. J. et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J. Clin. Oncol. 24, 2917\u20132931. https:\/\/doi.org\/10.1200\/jco.2006.06.5888 (2006).","journal-title":"J. Clin. Oncol."},{"key":"74087_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/humupd\/dms022","volume":"18","author":"S Morgan","year":"2012","unstructured":"Morgan, S., Anderson, R. A., Gourley, C., Wallace, W. H. & Spears, N. How do chemotherapeutic agents damage the ovary?. Hum. Reprod. Update 18, 525\u2013535. https:\/\/doi.org\/10.1093\/humupd\/dms022 (2012).","journal-title":"Hum. Reprod. Update"},{"key":"74087_CR36","doi-asserted-by":"publisher","first-page":"185162","DOI":"10.1126\/scitranslmed.3005402","volume":"5","author":"L Kalich-Philosoph","year":"2013","unstructured":"Kalich-Philosoph, L. et al. Cyclophosphamide triggers follicle activation and \u201cburnout\u201d; AS101 prevents follicle loss and preserves fertility. Sci. Transl. Med. 5, 185162. https:\/\/doi.org\/10.1126\/scitranslmed.3005402 (2013).","journal-title":"Sci. Transl. Med."},{"key":"74087_CR37","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.Ccr-18-1314","volume":"24","author":"PA Konstantinopoulos","year":"2018","unstructured":"Konstantinopoulos, P. A. & Matulonis, U. A. PARP inhibitors in ovarian cancer: A trailblazing and transformative journey. Clin. Cancer Res. 24, 4062\u20134065. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-1314 (2018).","journal-title":"Clin. Cancer Res."},{"key":"74087_CR38","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.fertnstert.2005.05.059","volume":"84","author":"PM Lam","year":"2005","unstructured":"Lam, P. M. & Haines, C. Vascular endothelial growth factor plays more than an angiogenic role in the female reproductive system. Fertil. Steril. 84, 1775\u20131778. https:\/\/doi.org\/10.1016\/j.fertnstert.2005.05.059 (2005).","journal-title":"Fertil. Steril."},{"key":"74087_CR39","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1095\/biolreprod.106.050880","volume":"76","author":"AE Roberts","year":"2007","unstructured":"Roberts, A. E. et al. Neutralization of endogenous vascular endothelial growth factor depletes primordial follicles in the mouse ovary. Biol. Reprod. 76, 218\u2013223. https:\/\/doi.org\/10.1095\/biolreprod.106.050880 (2007).","journal-title":"Biol. Reprod."},{"key":"74087_CR40","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/humupd\/dmn025","volume":"14","author":"JE Swain","year":"2008","unstructured":"Swain, J. E. & Pool, T. B. ART failure: Oocyte contributions to unsuccessful fertilization. Hum. Reprod. Update 14, 431\u2013446. https:\/\/doi.org\/10.1093\/humupd\/dmn025 (2008).","journal-title":"Hum. Reprod. Update"},{"key":"74087_CR41","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/mrd.1080260408","volume":"26","author":"BC Vanderhyden","year":"1990","unstructured":"Vanderhyden, B. C. & Armstrong, D. T. Effects of gonadotropins and granulosa cell secretions on the maturation and fertilization of rat oocytes in vitro. Mol. Reprod. Dev. 26, 337\u2013346. https:\/\/doi.org\/10.1002\/mrd.1080260408 (1990).","journal-title":"Mol. Reprod. Dev."},{"key":"74087_CR42","unstructured":"Food and Drug Administration. Oncology Pharmaceuticals: Reproductive Toxicity Testing and Labeling Recommendations Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/oncology-pharmaceuticals-reproductive-toxicity-testing-and-labeling-recommendations-guidance (2019)."},{"key":"74087_CR43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","volume":"19","author":"ER Copson","year":"2018","unstructured":"Copson, E. R. et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): A prospective cohort study. Lancet Oncol. 19, 169\u2013180. https:\/\/doi.org\/10.1016\/S1470-2045(17)30891-4 (2018).","journal-title":"Lancet Oncol."},{"key":"74087_CR44","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1200\/JCO.2009.24.2057","volume":"28","author":"K Oktay","year":"2010","unstructured":"Oktay, K., Kim, J. Y., Barad, D. & Babayev, S. N. Association of BRCA1 mutations with occult primary ovarian insufficiency: A possible explanation for the link between infertility and breast\/ovarian cancer risks. J. Clin. Oncol. 28, 240\u2013244. https:\/\/doi.org\/10.1200\/JCO.2009.24.2057 (2010).","journal-title":"J. Clin. Oncol."},{"key":"74087_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/1389450118666170711151518","volume":"19","author":"D Kamel","year":"2018","unstructured":"Kamel, D., Gray, C., Walia, J. S. & Kumar, V. PARP inhibitor drugs in the treatment of breast, ovarian, prostate and pancreatic cancers: An update of clinical trials. Curr. Drug Targets 19, 21\u201337. https:\/\/doi.org\/10.2174\/1389450118666170711151518 (2018).","journal-title":"Curr. Drug Targets"},{"key":"74087_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12887-019-1409-7","volume":"19","author":"M Takagi","year":"2019","unstructured":"Takagi, M. et al. Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: Study protocol. BMC Pediatr. 19, 31. https:\/\/doi.org\/10.1186\/s12887-019-1409-7 (2019).","journal-title":"BMC Pediatr."},{"key":"74087_CR47","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/molehr\/gaw051","volume":"22","author":"F Lopes","year":"2016","unstructured":"Lopes, F., Smith, R., Nash, S., Mitchell, R. T. & Spears, N. Irinotecan metabolite SN38 results in germ cell loss in the testis but not in the ovary of prepubertal mice. Mol. Hum. Reprod. 22, 745\u2013755. https:\/\/doi.org\/10.1093\/molehr\/gaw051 (2016).","journal-title":"Mol. Hum. Reprod."},{"key":"74087_CR48","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1210\/me.2012-1027","volume":"26","author":"Y Sato","year":"2012","unstructured":"Sato, Y., Cheng, Y., Kawamura, K., Takae, S. & Hsueh, A. J. C-type natriuretic peptide stimulates ovarian follicle development. Mol. Endocrinol. 26, 1158\u20131166. https:\/\/doi.org\/10.1210\/me.2012-1027 (2012).","journal-title":"Mol. Endocrinol."},{"key":"74087_CR49","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1530\/jrf.0.0170555","volume":"17","author":"T Pedersen","year":"1968","unstructured":"Pedersen, T. & Peters, H. Proposal for a classification of oocytes and follicles in the mouse ovary. J. Reprod. Fertil. 17, 555\u2013557. https:\/\/doi.org\/10.1530\/jrf.0.0170555 (1968).","journal-title":"J. Reprod. Fertil."},{"key":"74087_CR50","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1530\/jrf.0.0370277","volume":"37","author":"AG Byskov","year":"1974","unstructured":"Byskov, A. G. Cell kinetic studies of follicular atresia in the mouse ovary. J. Reprod. Fertil. 37, 277\u2013285. https:\/\/doi.org\/10.1530\/jrf.0.0370277 (1974).","journal-title":"J. Reprod. Fertil."},{"key":"74087_CR51","doi-asserted-by":"publisher","first-page":"10280","DOI":"10.1073\/pnas.1001198107","volume":"107","author":"J Li","year":"2010","unstructured":"Li, J. et al. Activation of dormant ovarian follicles to generate mature eggs. Proc. Natl. Acad. Sci. U. S. A. 107, 10280\u201310284. https:\/\/doi.org\/10.1073\/pnas.1001198107 (2010).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74087-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74087-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74087-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T21:14:36Z","timestamp":1670361276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74087-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["74087"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-74087-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,13]]},"assertion":[{"value":"2 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17058"}}